US FDA’s External Controls Guidance Should Include Hybrid Designs, Experts Say
Executive Summary
Also, FDA audits of vendors who curate and de-identify data could be a way of establishing data provenance without providing access to original patient records, which could trigger consent and privacy issues, experts said during a roundtable sponsored by the Clinical Research Data Sharing Alliance.
You may also be interested in...
US FDA External Controls Guidance Does Little To Advance The Cause, Especially In Rare Diseases – Comments
Industry and patient groups take issue with draft guidance’s skeptical tone on utility and reliability of externally controlled studies, with some saying the guidance ignores special considerations inherent in studying rare diseases. Recommendations on access to patient-level data for external control arms also are problematic and likely infeasible, stakeholders say.
External Controls: FDA Guidance Provides Clarity But Does Little To Remove Hurdles
Agency discourages use of externally controlled trials in all but a very limited number of situations truly ripe for such an approach; new draft guidance discusses at length the various confounding factors that can introduce bias into a comparison between an investigational treatment and an external control using either real-world data or data from another clinical trial.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.